JP2018524008A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524008A5
JP2018524008A5 JP2018501936A JP2018501936A JP2018524008A5 JP 2018524008 A5 JP2018524008 A5 JP 2018524008A5 JP 2018501936 A JP2018501936 A JP 2018501936A JP 2018501936 A JP2018501936 A JP 2018501936A JP 2018524008 A5 JP2018524008 A5 JP 2018524008A5
Authority
JP
Japan
Prior art keywords
candidate
neoantigens
peptide
neoantigen
candidate neoantigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018501936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524008A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/042288 external-priority patent/WO2017011660A1/en
Publication of JP2018524008A publication Critical patent/JP2018524008A/ja
Publication of JP2018524008A5 publication Critical patent/JP2018524008A5/ja
Pending legal-status Critical Current

Links

JP2018501936A 2015-07-14 2016-07-14 ネオアンチゲン分析 Pending JP2018524008A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192373P 2015-07-14 2015-07-14
US62/192,373 2015-07-14
PCT/US2016/042288 WO2017011660A1 (en) 2015-07-14 2016-07-14 Neoantigen analysis

Publications (2)

Publication Number Publication Date
JP2018524008A JP2018524008A (ja) 2018-08-30
JP2018524008A5 true JP2018524008A5 (https=) 2019-08-15

Family

ID=57757739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018501936A Pending JP2018524008A (ja) 2015-07-14 2016-07-14 ネオアンチゲン分析

Country Status (6)

Country Link
US (3) US10563266B2 (https=)
EP (2) EP3323070B1 (https=)
JP (1) JP2018524008A (https=)
CN (2) CN108351916A (https=)
CA (2) CA3255210A1 (https=)
WO (1) WO2017011660A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
US11514289B1 (en) 2016-03-09 2022-11-29 Freenome Holdings, Inc. Generating machine learning models using genetic data
JP7155470B2 (ja) * 2017-03-31 2022-10-19 エーシーティー ジェノミックス (アイピー) カンパニー リミテッド 免疫原性がん特異的エピトープのためのランク付けシステム
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
EP3688165A4 (en) 2017-09-25 2021-09-29 Nant Holdings IP, LLC VALIDATION OF THE PRESENTATION OF NEOEPITOPES
CN108491689B (zh) * 2018-02-01 2019-07-09 杭州纽安津生物科技有限公司 基于转录组的肿瘤新抗原鉴定方法
CN108388773B (zh) * 2018-02-01 2019-11-19 杭州纽安津生物科技有限公司 一种肿瘤新生抗原的鉴定方法
CN108796055B (zh) * 2018-06-12 2022-04-08 深圳裕策生物科技有限公司 基于二代测序的肿瘤新生抗原检测方法、装置和存储介质
EP3815091A4 (en) * 2018-06-29 2022-03-23 Rady Children's Hospital Research Center Method and system for sample identity assurance
EP3618071A1 (en) * 2018-08-28 2020-03-04 CeCaVa GmbH & Co. KG Methods for selecting tumor-specific neoantigens
EP3844776A1 (en) 2018-08-28 2021-07-07 CeCaVa GmbH & Co. KG Methods for ranking and/or selecting tumor-specific neoantigens
MX2021003654A (es) * 2018-09-27 2021-05-28 Nykode Therapeutics AS Metodo para seleccionar neoepitopes.
MX2021005656A (es) * 2018-11-15 2021-07-07 Nouscom Ag Seleccion de mutaciones de cancer para la generacion de una vacuna contra cancer personalizada.
JP7623281B2 (ja) 2018-11-15 2025-01-28 パーソナル ゲノム ダイアグノスティクス インコーポレイテッド 免疫療法で治療されたがん患者の応答の予測を改善する方法
CN109706065A (zh) * 2018-12-29 2019-05-03 深圳裕策生物科技有限公司 肿瘤新生抗原负荷检测装置及存储介质
CN109801678B (zh) * 2019-01-25 2023-07-25 上海鲸舟基因科技有限公司 基于全转录组的肿瘤抗原预测方法及其应用
CN111696628A (zh) * 2019-03-15 2020-09-22 痕准生物科技有限公司 新生抗原的鉴定方法
CN111755067A (zh) * 2019-03-28 2020-10-09 格源致善(上海)生物科技有限公司 一种肿瘤新生抗原的筛选方法
WO2020221783A1 (en) * 2019-04-29 2020-11-05 Vaccibody As Methods for pre-selection of neoepitopes
CN110600077B (zh) * 2019-08-29 2022-07-12 北京优迅医学检验实验室有限公司 肿瘤新抗原的预测方法及其应用
CN110706742B (zh) * 2019-09-30 2020-06-30 中生康元生物科技(北京)有限公司 泛癌种肿瘤新生抗原高通量预测方法及其应用
JP2023522512A (ja) * 2019-11-18 2023-05-31 エピヴァックス セラピューティクス インコーポレイテッド 共通のネオエピトープワクチンのための改善された組成物及び方法
JP7617574B2 (ja) * 2020-01-07 2025-01-20 コリア アドバンスド インスティテュート オブ サイエンス アンド テクノロジー 新生抗原をスクリーニングする方法、システム及びその用途
GB202006760D0 (en) * 2020-05-07 2020-06-24 Univ Helsinki Bioinformatics
CN112309502B (zh) * 2020-10-14 2024-09-20 深圳市新合生物医疗科技有限公司 一种计算肿瘤新抗原负荷的方法及系统
WO2022170067A1 (en) * 2021-02-05 2022-08-11 Amazon Technologies, Inc. Ranking neoantigens for personalized cancer vaccine
JP2024517793A (ja) 2021-04-30 2024-04-23 ティゲン・ファーマ・ソシエテ・アノニム 単一容器リンパ球拡大
US20220383996A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
US12537072B1 (en) 2021-05-27 2026-01-27 Amazon Technologies, Inc. Immunogenic response prediction based on major histocompatibility complex (MHC) data
US12518851B2 (en) * 2021-09-07 2026-01-06 Nec Corporation Binding peptide generation for MHC class I proteins with deep reinforcement learning for immunotherapy decision making
WO2024097864A1 (en) 2022-11-02 2024-05-10 Tigen Pharma Sa Expansion of lymphocytes
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
WO2025049577A2 (en) * 2023-08-29 2025-03-06 Foundation Medicine, Inc. Neoantigen feature selection for prioritization of potential immunotherapy targets

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US454A (en) 1837-11-04 Method obi constructing stoves
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
US6054276A (en) 1998-02-23 2000-04-25 Macevicz; Stephen C. DNA restriction site mapping
US6223128B1 (en) 1998-06-29 2001-04-24 Dnstar, Inc. DNA sequence assembly system
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
GB9901475D0 (en) 1999-01-22 1999-03-17 Pyrosequencing Ab A method of DNA sequencing
US6818395B1 (en) 1999-06-28 2004-11-16 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
AU7537200A (en) 1999-09-29 2001-04-30 Solexa Ltd. Polynucleotide sequencing
US7809509B2 (en) 2001-05-08 2010-10-05 Ip Genesis, Inc. Comparative mapping and assembly of nucleic acid sequences
US20060024681A1 (en) 2003-10-31 2006-02-02 Agencourt Bioscience Corporation Methods for producing a paired tag from a nucleic acid sequence and methods of use thereof
CA2615323A1 (en) 2005-06-06 2007-12-21 454 Life Sciences Corporation Paired end sequencing
US7329860B2 (en) 2005-11-23 2008-02-12 Illumina, Inc. Confocal imaging methods and apparatus
JP2009532664A (ja) * 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
CN100428254C (zh) * 2006-07-20 2008-10-22 上海交通大学 交叉反应抗原计算机辅助筛选的方法
US7754429B2 (en) 2006-10-06 2010-07-13 Illumina Cambridge Limited Method for pair-wise sequencing a plurity of target polynucleotides
US8262900B2 (en) 2006-12-14 2012-09-11 Life Technologies Corporation Methods and apparatus for measuring analytes using large scale FET arrays
EP2126766A2 (en) 2007-01-26 2009-12-02 Illumina Inc. Image data efficient genetic sequencing method and system
US8165821B2 (en) 2007-02-05 2012-04-24 Applied Biosystems, Llc System and methods for indel identification using short read sequencing
US8271206B2 (en) 2008-04-21 2012-09-18 Softgenetics Llc DNA sequence assembly methods of short reads
US20110257889A1 (en) 2010-02-24 2011-10-20 Pacific Biosciences Of California, Inc. Sequence assembly and consensus sequence determination
EP2569633B1 (en) * 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
LT2901341T (lt) 2012-09-28 2019-09-25 The University Of Connecticut Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui

Similar Documents

Publication Publication Date Title
JP2018524008A5 (https=)
JP6953515B2 (ja) 天然の内因性又は外因性細胞プロセシング、輸送及び主要組織適合遺伝子複合体(mhc)提示と正の関連性がある特徴量を含むペプチドを同定するための機械学習アルゴリズム
JP2025094018A5 (https=)
Paul et al. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes
Stranzl et al. NetCTLpan: pan-specific MHC class I pathway epitope predictions
Fisch et al. Integral use of immunopeptidomics and immunoinformatics for the characterization of antigen presentation and rational identification of BoLA-DR–presented peptides and epitopes
JP2017534257A5 (https=)
JP2022502416A5 (https=)
IL274799B2 (en) Reducing junction epitope presentation for neoantigens
JP2018524008A (ja) ネオアンチゲン分析
JP2020510698A5 (https=)
JP2016511406A5 (https=)
JP2017532544A5 (https=)
CN115298739A (zh) 利用肽序列及hla等位基因序列来预测新生抗原的方法及计算机程序
Harjanto et al. Clustering HLA class I superfamilies using structural interaction patterns
Tschochner et al. Identifying patient-specific Epstein-Barr nuclear antigen-1 genetic variation and potential autoreactive targets relevant to multiple sclerosis pathogenesis
CN115747327A (zh) 涉及移码突变的新抗原预测方法
JP6353894B2 (ja) Kir及びhla遺伝子型に基づいて同種造血細胞ドナーを選択するための方法及びアルゴリズム
JP2026065000A (ja) 免疫原性応答を誘発すると予測される1つ又は複数のソースタンパク質の1つ又は複数の候補領域を識別する方法及びシステム並びにワクチンを作製する方法
Moyer et al. Clinical outcomes of HLA‐DPB 1 mismatches in 10/10 HLA‐matched unrelated donor‐recipient pairs undergoing allogeneic stem cell transplant
KR20220151388A (ko) 펩타이드 신물질 탐색 방법 및 시스템
Kong et al. Improved prediction of allergenicity by combination of multiple sequence motifs
Rockberg et al. Prediction of antibody response using recombinant human protein fragments as antigen
Teh-Poot et al. Mining Trypanosoma cruzi genome sequences for antigen discovery and vaccine development
Hu et al. Ensemble approaches for improving HLA class I-peptide binding prediction